KYNB Kyntra Bio, Inc. - Common Stock
$7.18
价格 · 八月 19, 2026
截至...的财报数据 八月 13, 2026
52周区间
$6–$13
14% of range
分析师评级
BUY
9 analysts
目标价
$39
+444% upside
P/E (TTM)
0.2
ROE
-143.5%
净利润率
2848.6%
KYNB 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$7.17
市值
$29M
P/E (TTM)
0.2
每股收益 (TTM)
$45.37
营收 (TTM)
$6M
股息收益率
—
ROE
-143.5%
负债/权益
—
52周区间
$6 – $13
KYNB 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
Configure
10年表现 收入、净利润、利润率和每股收益趋势
营收与净利润
$6M
2016-12-31
→
2025-12-31
EPS
$45.37
2020-12-31
→
2025-12-31
自由现金流
$-5M
2016-12-31
→
2025-12-31
利润率
2848.6%
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
指标
5年趋势
KYNB
同行中位数
P/E (TTM)
0.2
0.1
P/S (TTM) (市销率 (TTM))
4.5
4.4
P/B (市净率)
-1.0
4.4
Price / FCF (股价/自由现金流)
-6.0
—
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
指标
5年趋势
KYNB
同行中位数
Operating Margin (营业利润率)
-712.7%
—
Net Profit Margin (净利润率)
2848.6%
39.0%
ROA
109.8%
-69.9%
ROE
-143.5%
-290.9%
ROIC
152.6%
—
财务健康 债务、流动性、偿付能力 — 资产负债表强度
指标
5年趋势
KYNB
同行中位数
Current Ratio (流动比率)
3.4
2.4
Quick Ratio (速动比率)
3.1
—
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
指标
5年趋势
KYNB
同行中位数
Revenue YoY (营收同比增长)
-78.3%
—
Revenue CAGR 3Y (营收3年复合年增长率)
-64.2%
—
Revenue CAGR 5Y (营收5年复合年增长率)
-48.4%
—
资本效率 资产周转率、库存周转率、应收账款周转率
指标
5年趋势
KYNB
同行中位数
KYNB 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
买入
9 位分析师
- 强烈买入 3 33.3%
- 买入 4 44.4%
- 持有 2 22.2%
- 卖出 0 0.0%
- 强烈卖出 0 0.0%
12个月价格目标
2 位分析师 · 2026-08-14
中位数
$39.00
← 低于所有目标
$7.17
最低
$35.00
最高
$43.00
中位数目标
$39.00
+443.6%
平均目标
$39.00
+443.6%
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
1.2%
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2026年6月30日 | $-4.68 | $-3.25 | -1.4% |
| 2026年3月31日 | $-3.76 | $-3.42 | -0.34% |
| 2025年12月31日 | $-3.61 | $-3.96 | 0.35% |
| 2025年9月30日 | $-3.25 | $-4.09 | 0.84% |
| 2025年6月30日 | $-1.88 | $-2.35 | 0.47% |
| 2025年3月31日 | $1.25 | $0.51 | 0.74% |
| 2024年12月31日 | $4.50 | $-3.57 | 8.1% |
同行比较（GICS 子行业） 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| KYNB | $36M | 0.2 | -78.3% | 2848.6% | -143.5% | — |
| DYAI | — | -4.1 | -11.6% | — | — | — |
| GRDX | $20M | -1.1 | — | -17634.4% | -68.6% | -1813.6% |
| LGVN | — | -0.4 | -49.9% | -1893.6% | -247.7% | 67.0% |
| SHPH | $4M | -0.3 | 0.00% | — | -400.1% | — |
| ATOS | $5M | -0.1 | — | — | -71.7% | — |
| BTAI | $36M | -0.3 | -71.7% | -10887.4% | 68.8% | — |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 16
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6M | $30M | $47M | $141M | $235M | $176M | $257M | $213M | $131M | $183M | $181M | $138M | |
| Cost of Revenue | $556.0K | $16M | $4M | $20M | $13M | $9M | $1M | · | · | · | · | · | |
| R&D Expense | $24M | $96M | $266M | $297M | $387M | $253M | $209M | $236M | $197M | $187M | $214M | $151M | |
| SG&A Expense | $28M | $49M | $86M | $125M | $124M | $106M | $135M | $64M | $52M | $46M | $44M | $37M | |
| Operating Expenses | $52M | $180M | $370M | $442M | $524M | $368M | $346M | $300M | $248M | $233M | $258M | $188M | |
| Operating Income | $-46M | $-150M | $-323M | $-301M | $-289M | $-192M | $-89M | $-87M | $-117M | $-50M | $-78M | $-50M | |
| Interest Expense | $9M | $8M | $8M | $1M | $1M | $2M | $3M | $11M | $10M | $11M | $11M | $11M | |
| Other Non-op | $3M | $5M | $8M | $8M | $-1M | $6M | $16M | · | · | · | · | · | |
| Pretax Income | $-58M | $-153M | $-323M | $-295M | $-291M | $-189M | $-77M | $-86M | $-121M | $-58M | $-86M | $-60M | |
| Income Tax | $-90.0K | $-269.0K | $-252.0K | $358.0K | $347.0K | $360.0K | $328.0K | $304.0K | $321.0K | $-71.0K | $242.0K | $0 | |
| Net Income | $183M | $-48M | $-284M | $-294M | $-290M | $-189M | $-77M | $-86M | $-121M | $-58M | $-86M | $-60M | |
| EPS (Basic) | $45.37 | $-11.89 | $-2.92 | $-3.14 | $-3.14 | $-2.11 | · | · | · | · | · | · | |
| EPS (Diluted) | $45.37 | $-11.89 | $-2.92 | $-3.14 | $-3.14 | $-2.11 | · | · | · | · | · | · | |
| Shares (Basic) | 4,043,000 | 4,002,000 | 97,303,000 | 93,582,000 | 92,349,000 | 89,854,000 | · | · | · | · | · | · | |
| Shares (Diluted) | 4,043,000 | 4,002,000 | 97,303,000 | 93,582,000 | 92,349,000 | 89,854,000 | · | · | · | · | · | · | |
| EBITDA | $-46M | $-150M | $-282M | $-301M | $-289M | $-192M | $-89M | $-87M | $-123M | $-54M | $-78M | · |
资产负债表 25
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $48M | $50M | $82M | $156M | $171M | $678M | $126M | $89M | $674M | $174M | $153M | $165M | |
| Short-term Investments | $41M | $0 | $122M | $266M | $234M | $8M | $407M | $532M | $62M | · | · | · | |
| Receivables | $216.0K | $481.0K | $5M | $16M | $17M | $42M | $28M | $64M | $8M | $10M | $15M | $13M | |
| Inventory | $4M | $3M | $17M | $40M | $31M | $17M | $7M | $0 | · | · | · | · | |
| Prepaid Expense | $6M | $32M | $40M | $14M | $20M | $10M | $133M | $5M | $5M | $3M | $4M | $5M | |
| Other Current Assets | $1M | $1M | $7M | $4M | $5M | $2M | $2M | $2M | · | · | · | · | |
| Current Assets | $99M | $197M | $332M | $493M | $474M | $755M | $702M | $690M | $749M | $267M | $201M | $198M | |
| PP&E (Net) | · | $0 | $5M | $21M | $28M | $34M | $43M | $127M | $129M | $124M | $129M | $132M | |
| PP&E (Gross) | · | $0 | $118M | $149M | $149M | $145M | $143M | $192M | $189M | $177M | $177M | $174M | |
| Accum. Depreciation | · | $0 | $113M | $129M | $121M | $111M | $100M | $65M | $60M | $54M | $48M | $42M | |
| Other Non-current Assets | $361.0K | $1M | $3M | $5M | $7M | $1M | $9M | $3M | $5M | $2M | $2M | $2M | |
| Total Assets | $120M | $215M | $424M | $610M | $774M | $827M | $857M | $881M | $899M | $470M | $471M | $484M | |
| Accounts Payable | $4M | $5M | $16M | $31M | $26M | $25M | $6M | $9M | $6M | $6M | $7M | $5M | |
| Accrued Liabilities | $20M | $62M | $133M | $220M | $173M | $118M | $84M | $66M | $64M | $51M | $48M | $49M | |
| Current Liabilities | $29M | $133M | $218M | $274M | $225M | $163M | $103M | $89M | $86M | $65M | $67M | $63M | |
| Capital Leases | · | $0 | $65M | $80M | $89M | $853.0K | $942.0K | $0 | · | · | · | · | |
| Other Non-current Liabilities | $82.0K | $822.0K | $3M | $6M | $26M | $39M | $65M | $10M | $8M | $6M | $5M | $696.0K | |
| Total Liabilities | $115M | $398M | $586M | $612M | $545M | $385M | $322M | $352M | $351M | $294M | $274M | $243M | |
| Common Stock | $1M | $1M | $988.0K | $942.0K | $929.0K | $914.0K | $877.0K | $854.0K | $825.0K | $637.0K | $620.0K | $590.0K | |
| Paid-in Capital | $1.68B | $1.67B | $1.64B | $1.54B | $1.48B | $1.40B | $1.30B | $1.23B | $1.16B | · | $587M | $546M | |
| Retained Earnings | $-1.71B | $-1.89B | $-1.84B | $-1.56B | $-1.26B | $-974M | $-785M | $-716M | $-631M | $-510M | $-452M | $-322M | |
| AOCI | $-2M | $-6M | $-7M | $-6M | $-4M | $-4M | $-747.0K | $-2M | $-2M | $-960.0K | $-2M | $-3M | |
| Stockholders' Equity | $-30M | $-226M | $-204M | $-21M | $209M | $422M | $516M | $509M | $528M | $156M | $178M | $221M | |
| Liabilities + Equity | $120M | $215M | $424M | $610M | $774M | $827M | $857M | $881M | $899M | $470M | $471M | $484M | |
| Shares Outstanding | 4,047,000 | 4,037,000 | 98,770,000 | 94,166,000 | 92,881,000 | 91,441,000 | 87,657,000 | 85,432,000 | 82,498,000 | 63,665,000 | 61,985,000 | 59,046,000 |
现金流 13
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $7M | $25M | $51M | $66M | $71M | $73M | $66M | $52M | $38M | $32M | $28M | $19M | |
| Deferred Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $-212.0K | $0 | $0 | |
| Restructuring | $553.0K | $19M | $13M | $0 | $0 | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-5M | $-138M | $-315M | $-146M | $-82M | $82M | $-79M | $-76M | $-67M | $7M | $-19M | $22M | |
| CapEx | $38.0K | $266.0K | $3M | $4M | $5M | $4M | $6M | $8M | $8M | $1M | $2M | $8M | |
| Investing Cash Flow | $35M | $126M | $154M | $89M | $-427M | $452M | $120M | $-522M | $70M | $7M | · | · | |
| Stock Issued | $0 | $139.0K | $4M | $4M | $13M | $38M | $21M | $30M | $35M | $10M | $15M | $2M | |
| Net Stock Activity | $0 | $139.0K | $4M | $4M | $13M | $38M | $21M | $30M | $35M | $10M | $13M | · | |
| Financing Cash Flow | $-86M | $-255.0K | $123M | $47M | $-563.0K | $13M | $-4M | $14M | $496M | $7M | · | · | |
| Net Change in Cash | $-54M | $-12M | $-42M | $-16M | $-507M | $552M | $37M | $-584M | $500M | $20M | $-12M | $89M | |
| Taxes Paid | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-5M | $-138M | $-318M | $-150M | $-87M | $78M | $-84M | $-84M | $-75M | $6M | $-21M | · | |
| Levered FCF | $-14M | $-146M | $-333M | $-151M | $-88M | $75M | $-87M | $-95M | $-85M | $-5M | $-32M | · |
盈利能力 7
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -712.7% | -507.8% | -190.7% | -213.9% | -122.6% | -108.8% | -34.8% | -40.7% | -97.6% | -29.9% | -42.9% | · | |
| Net Margin | 2848.6% | -160.6% | -192.4% | -208.7% | -123.2% | -107.4% | -30.0% | -40.6% | -100.4% | -34.4% | -47.4% | · | |
| Pretax Margin | -905.2% | -517.8% | -194.2% | -209.5% | -123.5% | -107.1% | -29.9% | -40.4% | -100.2% | -34.4% | -47.3% | · | |
| EBITDA Margin | -712.7% | -507.8% | -190.7% | -213.9% | -122.6% | -108.8% | -34.8% | -40.7% | -97.6% | -29.9% | -42.9% | · | |
| ROA | 109.8% | -14.9% | -55.0% | -42.4% | -36.2% | -22.5% | -8.9% | -9.7% | -18.4% | -13.1% | -18.0% | · | |
| ROE | -143.5% | 22.1% | 252.0% | -312.9% | -91.9% | -40.4% | -15.0% | -16.7% | -35.1% | -37.0% | -43.0% | · | |
| ROIC | 152.6% | 66.6% | 138.0% | 1405.3% | -138.1% | -45.5% | -17.4% | -17.1% | -21.8% | -34.4% | -43.8% | · |
流动性与偿付能力 3
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 1.5 | 1.5 | 1.8 | 2.1 | 4.6 | 6.8 | 7.8 | 9.7 | 4.1 | 3.0 | · | |
| Quick Ratio | 3.1 | 0.4 | 1.1 | 1.6 | 1.9 | 4.5 | 5.5 | 7.7 | 8.8 | 2.8 | 2.5 | · | |
| Interest Coverage | -5.2 | -18.2 | -18.1 | -209.0 | -268.4 | -79.9 | -31.1 | -7.9 | -12.6 | -5.0 | -7.0 | · |
效率 3
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | 0.3 | 0.2 | 0.3 | 0.2 | 0.3 | 0.2 | 0.2 | 0.4 | 0.4 | · | |
| Inventory Turnover | 0.2 | 1.5 | 0.5 | 0.6 | 0.5 | · | · | · | · | · | · | · | |
| Receivables Turnover | 18.5 | 10.6 | 10.2 | 8.4 | 7.9 | 5.0 | 5.6 | 5.9 | 13.3 | 13.9 | 12.5 | · |
增长率 3
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -78.3% | -36.7% | -66.7% | -40.2% | 33.5% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -64.2% | -49.9% | -35.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -48.4% | · | · | · | · | · | · | · | · | · | · | · |
估值 (TTM) 9
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $6M | $30M | $47M | $141M | $235M | $176M | $257M | $213M | $131M | $183M | $181M | $138M | |
| Net Income TTM | $183M | $-48M | $-284M | $-294M | $-290M | $-189M | $-77M | $-86M | $-121M | $-58M | $-86M | $-60M | |
| Market Cap | $36M | $1.34B | · | · | · | · | · | · | · | · | · | · | |
| P/E | 0.2 | -1.1 | · | · | · | · | · | · | · | · | · | · | |
| P/S | 5.5 | 45.1 | · | · | · | · | · | · | · | · | · | · | |
| P/B | -1.2 | -5.9 | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | -7.4 | -9.7 | · | · | · | · | · | · | · | · | · | · | |
| P / FCF | -7.4 | -9.7 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 516.7% | -89.7% | · | · | · | · | · | · | · | · | · | · |
损益表 16
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $-1M | $4M | $1M | $1M | $1M | $3M | $3M | $123.0K | $998.0K | $25M | $-74M | $40M | $44M | $36M | $34M | $16M | |
| Cost of Revenue | $2.0K | $4M | $277.0K | $-58.0K | $85.0K | $252.0K | $-6M | $-75.0K | $140.0K | $21M | $-9M | $4M | $6M | $3M | $5M | $4M | |
| R&D Expense | $7M | $8M | $7M | $1M | $6M | $9M | $7M | $20M | $32M | $36M | $35M | $61M | $95M | $74M | $62M | $75M | |
| SG&A Expense | $9M | $6M | $7M | $5M | $7M | $8M | $8M | $9M | $15M | $17M | $-5M | $26M | $31M | $34M | $34M | $30M | |
| Operating Expenses | $16M | $18M | $15M | $6M | $13M | $18M | $10M | $48M | $47M | $75M | $21M | $104M | $132M | $112M | $101M | $109M | |
| Operating Income | $-18M | $-14M | $-14M | $-5M | $-12M | $-15M | $-7M | $-48M | $-46M | $-49M | $-95M | $-63M | $-88M | $-76M | $-66M | $-94M | |
| Interest Expense | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $-2M | $5M | $3M | $2M | $1M | $84.0K | |
| Other Non-op | $975.0K | $1M | $1M | $931.0K | $286.0K | $413.0K | $689.0K | $1M | $900.0K | $2M | $-390.0K | $4M | $3M | $1M | $921.0K | $2M | |
| Pretax Income | $12M | $-15M | $-15M | $-13M | $-14M | $-17M | $-9M | $-48M | $-47M | $-49M | $-93M | $-64M | $-88M | $-77M | $-66M | $-92M | |
| Income Tax | $-1.0K | $0 | $0 | $0 | $-92.0K | $2.0K | $2.0K | $3.0K | $-281.0K | $7.0K | $-175.0K | $84.0K | $-235.0K | $74.0K | $108.0K | $114.0K | |
| Net Income | $12M | $-15M | $-14M | $201M | $-8M | $5M | $18M | $-17M | $-16M | $-33M | $-56M | $-64M | $-88M | $-77M | $-66M | $-92M | |
| EPS (Basic) | $2.96 | $-3.76 | $-2.41 | $49.61 | $-1.88 | $1.15 | $-3.42 | $-4.25 | $-3.89 | $-0.33 | $-0.56 | $-0.65 | $-0.90 | $-0.81 | $-0.70 | $-0.98 | |
| EPS (Diluted) | $2.96 | $-3.76 | $-2.41 | $49.61 | $-1.88 | $1.15 | $-3.42 | $-4.25 | $-3.89 | $-0.33 | $-0.56 | $-0.65 | $-0.90 | $-0.81 | $-0.70 | $-0.98 | |
| Shares (Basic) | 4,048,000 | 4,047,000 | -104,997,000 | 4,044,000 | 4,042,000 | 4,038,000 | -102,994,000 | 4,021,000 | 3,993,000 | 98,982,000 | -193,362,000 | 98,245,000 | 97,729,000 | 94,691,000 | -186,703,000 | 93,767,000 | |
| Shares (Diluted) | 4,048,000 | 4,047,000 | -104,997,000 | 4,044,000 | 4,042,000 | 4,038,000 | -102,994,000 | 4,021,000 | 3,993,000 | 98,982,000 | -193,362,000 | 98,245,000 | 97,729,000 | 94,691,000 | -186,703,000 | 93,767,000 | |
| EBITDA | $-18M | $-14M | · | $-5M | $-12M | $-15M | · | $-17M | $-11M | $-31M | · | $-63M | $-88M | $-76M | · | $-94M |
资产负债表 25
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $51M | $37M | $48M | $118M | $23M | $34M | $50M | $131M | $141M | $106M | $82M | $121M | $153M | $189M | $156M | $156M | |
| Short-term Investments | $41M | $50M | $41M | · | · | · | $0 | $0 | $0 | $72M | $122M | $130M | $183M | $167M | $266M | $253M | |
| Receivables | $347.0K | $5M | $216.0K | $121.0K | $136.0K | $147.0K | $481.0K | $29M | $6M | $37M | $5M | $32M | $26M | $18M | $16M | $15M | |
| Inventory | $3M | $3M | $4M | $4M | $4M | $3M | $3M | $24M | $25M | $27M | $17M | $41M | $41M | $42M | $40M | $40M | |
| Prepaid Expense | $2M | $6M | $6M | $11M | $2M | $3M | $32M | $61M | $37M | $36M | $40M | $40M | $9M | $14M | $14M | $10M | |
| Other Current Assets | $833.0K | $556.0K | $1M | $695.0K | $1M | $1M | $1M | $3M | $4M | $2M | $7M | · | · | · | $4M | · | |
| Current Assets | $97M | $101M | $99M | $133M | $162M | $149M | $197M | $245M | $209M | $278M | $332M | $364M | $411M | $431M | $493M | $474M | |
| PP&E (Net) | · | · | · | · | · | · | · | $8M | $11M | $12M | $5M | $15M | $17M | $19M | $21M | $22M | |
| PP&E (Gross) | · | · | · | · | · | · | · | · | · | · | $118M | · | · | · | $149M | · | |
| Accum. Depreciation | · | · | · | · | · | · | · | · | · | · | $113M | · | · | · | $129M | · | |
| Other Non-current Assets | $241.0K | $248.0K | $361.0K | $556.0K | $839.0K | $1M | $1M | $3M | $3M | $3M | $3M | $4M | $4M | $5M | $5M | $5M | |
| Total Assets | $101M | $110M | $120M | $137M | $178M | $165M | $215M | $264M | $293M | $366M | $424M | $460M | $515M | $539M | $610M | $609M | |
| Accounts Payable | $8M | $5M | $4M | $5M | $10M | $7M | $5M | $9M | $10M | $4M | $16M | $19M | $13M | $71M | $31M | $19M | |
| Accrued Liabilities | $23M | $17M | $20M | $26M | $36M | $35M | $62M | $151M | $114M | $164M | $133M | $171M | $163M | $157M | $220M | $214M | |
| Current Liabilities | $36M | $28M | $29M | $36M | $156M | $73M | $133M | $191M | $149M | $197M | $218M | $209M | $194M | $255M | $274M | $252M | |
| Capital Leases | · | · | · | · | · | · | · | $707.0K | $58M | $63M | $65M | $70M | $74M | $77M | $80M | $81M | |
| Other Non-current Liabilities | $67.0K | $76.0K | $82.0K | $98.0K | $106.0K | $830.0K | $822.0K | $837.0K | $1M | $4M | $3M | $4M | $5M | $7M | $6M | $14M | |
| Total Liabilities | $109M | $119M | $115M | $120M | $359M | $340M | $398M | $466M | $484M | $552M | $586M | $576M | $575M | $567M | $612M | $563M | |
| Common Stock | $41.0K | $40.0K | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $995.0K | $988.0K | $983.0K | $982.0K | $966.0K | $942.0K | $939.0K | |
| Paid-in Capital | $1.68B | $1.68B | $1.68B | $1.68B | $1.67B | $1.67B | $1.67B | $1.67B | $1.66B | $1.65B | $1.64B | $1.63B | $1.63B | $1.59B | $1.54B | $1.52B | |
| Retained Earnings | $-1.71B | $-1.72B | $-1.71B | $-1.69B | $-1.89B | $-1.88B | $-1.89B | $-1.91B | $-1.89B | $-1.87B | $-1.84B | $-1.79B | $-1.72B | $-1.63B | $-1.56B | $-1.49B | |
| AOCI | $-1M | $-2M | $-2M | $-2M | $-5M | $-4M | $-6M | $-6M | $-4M | $-7M | $-7M | $-7M | $-6M | $-5M | $-6M | $-7M | |
| Stockholders' Equity | $-30M | $-44M | $-30M | $-17M | $-223M | $-217M | $-226M | $-244M | $-232M | $-228M | $-204M | $-157M | $-102M | $-49M | $-21M | $26M | |
| Liabilities + Equity | $101M | $110M | $120M | $137M | $178M | $165M | $215M | $264M | $293M | $366M | $424M | $460M | $515M | $539M | $610M | $609M | |
| Shares Outstanding | 4,049,000 | 4,048,000 | 4,047,000 | 4,045,000 | 4,044,000 | 101,044,000 | 4,037,000 | 100,770,000 | 100,400,000 | 99,474,000 | 98,770,000 | 98,339,000 | 98,204,000 | 96,623,000 | 94,166,000 | 93,936,000 |
现金流 11
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $984.0K | $1M | $1M | $662.0K | $2M | $3M | $178.0K | $8M | $9M | $9M | $9M | $9M | $16M | $16M | $16M | $16M | |
| Restructuring | $11.0K | $22.0K | $-7.0K | $41.0K | $393.0K | $126.0K | $900.0K | $19M | $0 | $0 | $0 | $13M | · | · | $0 | $0 | |
| Operating Cash Flow | $-4M | $-14M | $-18M | $-2M | $13M | $3M | $-30M | $-8M | $-40M | $-59M | $-18M | $-85M | $-111M | $-102M | $-53M | $-52M | |
| CapEx | $0 | $0 | $0 | $9.0K | $13.0K | $16.0K | $141.0K | $82.0K | $14.0K | $29.0K | $251.0K | $684.0K | $993.0K | $591.0K | $333.0K | $865.0K | |
| Investing Cash Flow | $18M | $3M | $-52M | $87M | $-13.0K | $-16.0K | $2M | $755.0K | $72M | $51M | $10M | $54M | $-14M | $103M | $1M | $45M | |
| Stock Issued | · | · | $0 | $0 | · | · | $23.0K | $0 | $116.0K | $0 | $45.0K | $0 | $3M | $907.0K | $1M | $210.0K | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $907.0K | · | · | |
| Financing Cash Flow | $-5.0K | $-7.0K | $-14.0K | $-86M | $-9.0K | $-88.0K | $5.0K | $-127.0K | $32.0K | $-165.0K | $-246.0K | $-22.0K | $92M | $31M | $49M | $-1M | |
| Net Change in Cash | $14M | $-11M | $-70M | $-2M | $14M | $4M | $-29M | $-10M | $35M | $-8M | $-7M | $-32M | $-36M | $33M | $-260.0K | $-12M | |
| Free Cash Flow | · | $-14M | · | · | · | $3M | · | · | · | $-59M | · | · | · | $-102M | · | · | |
| Levered FCF | · | $-16M | · | · | · | $445.7K | · | · | · | $-64M | · | · | · | $-105M | · | · |
盈利能力 7
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 1192.3% | -369.7% | · | -502.9% | -894.1% | -544.7% | · | -36.2% | -21.6% | -55.6% | · | -158.2% | -198.7% | -210.4% | · | -595.2% | |
| Net Margin | -812.4% | -406.6% | · | 18646.5% | -564.0% | 169.4% | · | -36.9% | -30.7% | -58.9% | · | -158.5% | -197.8% | -212.1% | · | -582.5% | |
| Pretax Margin | -812.3% | -404.8% | · | -1221.8% | -1021.9% | -612.0% | · | -38.8% | -33.5% | -59.9% | · | -160.0% | -199.6% | -214.1% | · | -584.3% | |
| EBITDA Margin | 1192.3% | -369.7% | · | -502.9% | -894.1% | -544.7% | · | -36.2% | -21.6% | -55.6% | · | -158.2% | -198.7% | -210.4% | · | -595.2% | |
| ROA | 8.6% | -11.1% | · | 100.0% | -3.2% | 1.8% | · | -4.7% | -3.9% | -7.3% | · | -11.9% | -14.6% | -11.9% | · | -12.6% | |
| ROE | -9.5% | 11.7% | · | -153.9% | 3.3% | -2.1% | · | 8.5% | 9.3% | 23.8% | · | 97.2% | -11644.1% | -140.5% | · | -52.1% | |
| ROIC | 58.3% | 31.6% | · | 31.8% | 5.4% | 6.9% | · | 6.9% | 4.6% | 13.6% | · | 40.4% | 85.9% | 155.9% | · | -356.5% |
流动性与偿付能力 3
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.7 | 3.6 | · | 3.7 | 1.0 | 2.0 | · | 1.3 | 1.4 | 1.4 | · | 1.7 | 2.1 | 1.7 | · | 1.9 | |
| Quick Ratio | 2.5 | 3.3 | · | 3.3 | 0.2 | 0.5 | · | 0.8 | 1.0 | 1.1 | · | 1.4 | 1.9 | 1.5 | · | 1.7 | |
| Interest Coverage | -7.4 | -5.7 | · | -2.6 | -6.0 | -6.6 | · | -3.4 | -2.3 | -6.2 | · | -12.6 | -28.7 | -32.1 | · | -1115.0 |
效率 3
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | -0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.0 | |
| Inventory Turnover | 0.0 | 1.3 | · | -0.0 | 0.0 | 0.0 | · | 0.2 | 0.2 | 0.7 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | -6.1 | 1.4 | · | 0.1 | 0.4 | 0.1 | · | 1.5 | 3.2 | 2.0 | · | 1.7 | 1.5 | 1.2 | · | 0.6 |
估值 (TTM) 9
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $5M | $9M | · | $5M | $5M | $29M | · | $67M | $111M | $146M | · | $136M | $126M | $143M | · | $262M | |
| Net Income TTM | $190M | $182M | · | $181M | $-36M | $-61M | · | $-129M | $-200M | $-261M | · | $-320M | $-329M | $-304M | · | $-178M | |
| Market Cap | $31M | $27M | · | $50M | $21M | $783M | · | $1.01B | $2.24B | $5.84B | · | · | · | · | · | · | |
| P/E | 0.2 | 0.2 | · | 0.3 | -0.5 | -0.9 | · | -1.1 | -3.9 | -21.8 | · | · | · | · | · | · | |
| P/S | 6.5 | 3.1 | · | 9.4 | 4.1 | 26.8 | · | 15.1 | 20.2 | 40.0 | · | · | · | · | · | · | |
| P/B | -1.0 | -0.6 | · | -2.9 | -0.1 | -3.6 | · | -4.1 | -9.6 | -25.6 | · | · | · | · | · | · | |
| P / Cash Flow | · | -2.0 | · | · | · | 288.0 | · | · | · | -98.6 | · | · | · | · | · | · | |
| P / FCF | · | -2.0 | · | · | · | 289.7 | · | · | · | -98.5 | · | · | · | · | · | · | |
| Earnings Yield | 621.6% | 665.5% | · | 355.4% | -188.1% | -108.7% | · | -91.4% | -25.9% | -4.6% | · | · | · | · | · | · |
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
损益表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 收入 | $6M | $30M | $47M | $141M | $235M |
| 营业利润率 % | -712.7% | -507.8% | -190.7% | -213.9% | -122.6% |
| 净收入 | $183M | $-48M | $-284M | $-294M | $-290M |
| 稀释后每股收益 (EPS) | $45.37 | $-11.89 | $-2.92 | $-3.14 | $-3.14 |
资产负债表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 流动比率 | 3.4 | 1.5 | 1.5 | 1.8 | 2.1 |
| 速动比率 | 3.1 | 0.4 | 1.1 | 1.6 | 1.9 |
现金流
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 自由现金流 | $-5M | $-138M | $-318M | $-150M | $-87M |
我的指标 您的个人关注列表 — 来自完整基本面的选定行
📊
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存，并会跟随您浏览所有股票。
机构持有人 (13F) 33 家申报者 · $6.9M 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 4 (-4 与上一季度对比) | 5 (-1 与上一季度对比) | 2 (-4 与上一季度对比) | 7 (+1 与上一季度对比) | -31K |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
公司内部人士 29 位内幕人士 · 11 位高管 · 20 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Thane Wettig | CEO | 2026年6月6日 F | 27005 | 0 | 0 | $0 |
| Enrique A Conterno | Chief Executive Officer | 2023年7月7日 S | 374722 | 0 | 0 | $0 |
| Thomas B Neff | Chief Executive Officer | 2019年8月22日 M | 44238 | 0 | 0 | $0 |
| David Delucia | Chief Financial Officer | 2026年6月6日 F | 4377 | 0 | 0 | $0 |
| Juan Graham | Chief Financial Officer | 2023年12月7日 F | 172618 | 0 | 0 | $0 |
| Pat Controneo | Executive Advisor & Former CFO | 2021年9月7日 F | 274536 | 0 | 0 | $0 |
| Christine Chung | SVP, China Operations | 2023年12月6日 F | 334837 | 0 | 0 | $0 |
| Mark Eisner | EVP, Chief Medical Officer | 2023年9月6日 F | 159917 | 0 | 0 | $0 |
| Elias Kouchakji | SVP, Clinical Dev, Drug Safety | 2021年3月8日 F | 147346 | 0 | 0 | $0 |
| Peony K Yu | Chief Medical Officer | 2020年12月16日 S | 192292 | 0 | 0 | $0 |
| Frank H Valone MD | Chief Medical Officer | 2016年4月1日 M | 104684 | 0 | 0 | $0 |
| Maykin Ho | 董事 | 2026年6月12日 A | 31501 | 0 | 0 | $0 |
| James A Schoeneck | 董事 | 2026年6月12日 A | 73722 | 0 | 0 | $0 |
| Michael Kauffman | 董事 | 2026年6月12日 A | — | 0 | 0 | $0 |
| Jeffrey L Edwards | 董事 | 2026年6月12日 A | 33977 | 0 | 0 | $0 |
| Jeffrey William Henderson | 董事 | 2023年9月1日 S | 28866 | 0 | 0 | $0 |
| Benjamin Cravatt | 董事 | 2023年6月7日 A | 28736 | 0 | 0 | $0 |
| Suzanne Blaug | 董事 | 2023年6月7日 A | 29594 | 0 | 0 | $0 |
| Gerald Lema | 董事 | 2023年6月7日 A | 28766 | 0 | 0 | $0 |
| Aoife Brennan | 董事 | 2023年6月7日 A | 27947 | 0 | 0 | $0 |
| Thomas F Kearns JR | 董事 | 2021年9月15日 S | 39764 | 0 | 0 | $0 |
| Kalevi Kurkijarvi | 董事 | 2021年5月26日 A | 37800 | 0 | 0 | $0 |
| Rory B Riggs | 董事 | 2021年5月26日 A | 395750 | 0 | 0 | $0 |
| Roberto Pedro Rosenkranz | 董事 | 2020年6月9日 M | 96100 | 0 | 0 | $0 |
| Toshinari Tamura | 董事 | 2019年6月5日 A | 56400 | 0 | 0 | $0 |
| Jorma Routti | 董事 | 2019年3月26日 M | 161540 | 0 | 0 | $0 |
| Julian N Stern | 董事 | 2016年6月8日 A | 161068 | 0 | 0 | $0 |
| Miguel Madero | 董事 | 2015年12月8日 M | 55614 | 0 | 0 | $0 |
| Astellas Pharma Inc. | — | 2014年11月19日 C | 4968367 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 2 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。